Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2025-05-31
Target enrollment:
Participant gender:
Summary
This phase II trial investigates the effect of olaparib in treating patients with castration
resistant prostate adenocarcinoma. Olaparib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.